Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

10820	Companies
234646	Keywords
163503	Articles
125574	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 06/13/2024 at 13:05, 2 years 1 month ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
BRIEF

published on 06/13/2024 at 13:05, 2 years 1 month ago

Moderna annonce des données positives d'efficacité de phase 3 pour l'ARNm-1283, le vaccin COVID-19 de nouvelle génération de la société

Moderne ARNm-1283 Vaccin Contre Le Covid-19 Essai De Phase 3 Données D'efficacité
PRESS RELEASE

published on 06/13/2024 at 13:00, 2 years 1 month ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 2 years 2 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
BRIEF

published on 06/10/2024 at 12:35, 2 years 2 months ago

Moderna annonce des données positives de phase 3 pour un vaccin combiné contre la grippe et le COVID-19

Moderne Vaccin Contre Le Covid-19 Essai De Phase 3 ARNm-1083 Grippe
PRESS RELEASE

published on 06/10/2024 at 12:30, 2 years 2 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 2 years 2 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
BRIEF

published on 06/07/2024 at 16:35, 2 years 2 months ago

Moderna dépose une demande auprès de la FDA pour le vaccin JN.1 ciblant la COVID-19

FDA Moderne COVID 19 Spikevax Variante JN.1
PRESS RELEASE

published on 06/07/2024 at 16:30, 2 years 2 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 2 years 2 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 08/12/2026 at 00:00, 3 hours 10 minutes ago

Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 3 hours 30 minutes ago

RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 3 hours 55 minutes ago

Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 4 hours 10 minutes ago

Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 4 hours 15 minutes ago

NV Gold Announces Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 00:18, 2 hours 52 minutes ago

EQS-Adhoc: Hawesko Holding SE updates forecast for the 2026 financial year
Published on 08/11/2026 at 22:10, 5 hours ago

Quantinuum Reports Second Quarter 2026 Results
Published on 08/11/2026 at 22:05, 5 hours 5 minutes ago

Quantinuum and Oracle Partner to Accelerate Hybrid Quantum Compute Adoption on Oracle Cloud Infrastructure
Published on 08/11/2026 at 18:59, 8 hours 11 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: SOEC realignment leads to adjustment of FY 2025/26 EBIT guidance; Order intake and sales outlook updated based on current business performance
Published on 08/11/2026 at 18:02, 9 hours 8 minutes ago

TerraMaster lance officiellement son programme de mise à niveau du stockage : boostez votre capacité de stockage pour entrer dans l’ère de l’IA

Les Echos

Published on 08/11/2026 at 17:45, 9 hours 25 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 9 hours 30 minutes ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 9 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 9 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 1 day 9 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE